TRVI Trevi Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Trevi Therapeutics, Inc. (TRVI) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 17, 2026, a 10-Q quarterly report filed on November 13, 2025, an 8-K current report filed on April 17, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Trevi Therapeutics, Inc. (TRVI) (SEC CIK 1563880), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Clinical-stage biopharmaceutical developing oral nalbuphine ER (Haduvio) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients
- • New emphasis: Initiation of two pivotal Phase 3 trials for IPF-related chronic cough in 2026 after positive Phase 2b CORAL results showing 47.9%-60.2% reduction in cough frequency
Risk Factors
- • Regulatory risk: ongoing FDA review of Phase 3 trials for Haduvio dosing; first trial to enroll ~300 patients starting Q2 2026
- • Geopolitical/macro risk: planned Phase 2b RCC trial across UK, Canada, and Europe, subject to international regulatory approvals
Management Discussion & Analysis
- • Revenue $0, no change YoY; no commercial product sales reported
- • Net loss $130M, operating margin not applicable due to no revenues
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 17, 2026
- • Full details in Exhibit 99.1 press release — key figures not disclosed in filing body
Item 8.01: Other Events
- • FDA End-of-Phase 2 meeting yielded full alignment on IPF-related chronic cough development plan — key regulatory de-risking milestone
- • Two pivotal Phase 3 trials to run in parallel: ~300-patient/52-week trial (primary endpoint at 24 weeks) + ~130-patient/12-week trial
Annual Reports Archive10-K
AI-powered analysis of Trevi Therapeutics, Inc. (TRVI) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Trevi Therapeutics, Inc. (TRVI) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Profitability | |||||
| Operating Income | -$32.5M | -$29.9M | -$33.9M | -$51.5M | -$49.3M |
| Net Income | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| Balance Sheet | |||||
| Total Assets | $38.5M | $123.0M | $89.4M | $110.9M | $193.4M |
| Equity | $17.1M | $107.5M | $82.5M | $99.6M | $183.2M |
| ROE | -198.8% | -27.1% | -35.2% | -48.1% | -23.3% |
Source: XBRL financial data from Trevi Therapeutics, Inc. (TRVI) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 17, 2026 | — | — | — |
8-K | Mar 17, 2026 | — | Analysis | — |
10-K | Mar 17, 2026 | Dec 31, 2025 | Analysis | |
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Dec 5, 2025 | — | — | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Mar 18, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Mar 20, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | — | |
10-Q | May 11, 2023 | Mar 31, 2023 | — | |
10-K | Mar 16, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 11, 2022 | Jun 30, 2022 | — | |
10-Q | May 12, 2022 | Mar 31, 2022 | — | |
10-K | Mar 17, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 10, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 12, 2021 | Jun 30, 2021 | — | |
10-Q | May 13, 2021 | Mar 31, 2021 | — | |
10-K | Mar 25, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest TRVI SEC filings in 2026?
Trevi Therapeutics, Inc. (TRVI) has filed a 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on April 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TRVI file its most recent 10-K annual report?
Trevi Therapeutics, Inc. (TRVI) filed its most recent 10-K annual report on March 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TRVI 10-Q quarterly reports?
Trevi Therapeutics, Inc. (TRVI)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every TRVI 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TRVI filed recently?
Trevi Therapeutics, Inc. (TRVI)'s most recent 8-K was filed on April 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TRVI insider trading activity (Form 4)?
SignalX aggregates every TRVI Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TRVI file with the SEC?
Trevi Therapeutics, Inc. (TRVI) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TRVI filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Trevi Therapeutics, Inc. (TRVI).
What is TRVI's SEC CIK number?
Trevi Therapeutics, Inc. (TRVI)'s SEC CIK (Central Index Key) number is 1563880. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1563880 to look up all TRVI filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TRVI return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Trevi Therapeutics, Inc. (TRVI) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Trevi Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.